This page shows you the latest news items in this category. This is page number 11.
Total 2840 results found since Jan 2013.
New Issue of Johns Hopkins Nursing Magazine
.ReadMsgBody{
width:100%;
background-color:#ffffff;
}
.ExternalClass{
width:100%;
background-color:#ffffff;
}
.ExternalClass,.ExternalClass p,.ExternalClass span,.ExternalClass font,.ExternalClass td,.ExternalClass div{
line-height:100%;
}
html{
width:100%;
}
body{
-webkit-text-size-adjust:none;
-ms-text-size-adjust:none;
}
body{
margin:0;
padding:0;
}
table{
border-spacing:0;
}
img{
display:block !important;
}
table td{
border-collapse:collapse;
}
.yshortcuts a{
border-bottom:none !important;
}
a{
color:#005EB8;
text-decoration:n...
Source: Johns Hopkins University and Health Systems Archive - May 4, 2022 Category: Nursing Source Type: news
Toilet warning: Scented toilet paper could be hiking your risk of seven health problems
WHEN you are browsing the toilet paper aisle, you might scam the price tags until you spot the cheapest loo roll. But if the factor that determines your purchase is a scent, you could be putting yourself at a health risk. An expert details how the use of scented toilet paper can hike the risk of seven health problems.
Source: Daily Express - Health - April 30, 2022 Category: Consumer Health News Source Type: news
NASA ’s Far-Flung Space Fleet Is Getting a Few Extra Years to Explore the Cosmos
It’s not hard to keep track of NASA’s big-ticket items—the high visibility spacecraft that generally carry equally high price tags and make very big headlines. There’s the $150 billion International Space Station; the $10 billion James Webb Space Telescope; the $2.4 billion Perseverance Mars rover; and then, of course, the trouble-plagued, $4.1 billion-per-flight Space Launch System moon rocket. That’s an impressive handful for any national space agency.
But NASA is more than its marquee missions. Much less discussed by most folks is the flock of spacecraft the space agency is operating throug...
Source: TIME: Science - April 29, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized healthscienceclimate Source Type: news
Scientific evidence supporting the government response to coronavirus (COVID-19), SAGE (updated 29th April 2022)
Evidence considered by the Scientific Advisory Group for Emergencies (SAGE).
29 April 2022Updated attendance lists for SAGE 16 and SAGE 52. Added HTML for 3 more papers.
8 April 2022We ' ve added 38 papers under February to December 2020, and 6 new papers under January, March and June 2021. We ' ve also published 6 medium-term projections that were considered during a week in which no SAGE was held.
Source: Current Awareness Service for Health (CASH) - April 29, 2022 Category: Consumer Health News Source Type: news
Fujitsu partners in Japan on AI for pancreatic cancer
Fujitsu is partnering with a Japanese hospital on developing artificial intelligenc...Read more on AuntMinnie.comRelated Reading:
GE, Fujitsu lead research effort on AI for brain aneurysms
Fujitsu develops AI to analyze CT studies
Fujitsu: RFID tags are suitable for MRI use
IDX, Fujitsu cancel NHS collaboration
Fujitsu to showcase MO storage options
Source: AuntMinnie.com Headlines - April 25, 2022 Category: Radiology Source Type: news
What is in the Differential Diagnosis for Red, Orange or Yellow Skin Conditions?
Discussion
This is the first in a short case series of differential diagnoses of colored skin conditions.
A differential diagnosis by distribution and common pattern can be found here.
For green, blue and violet conditions, a review can be found here.
For black and white conditions, a review can be found here.
For brown and grey conditions, a review can be found here.
Note that any color can be a normal variant for an individual or is physiologic for a given state.
The skin is the largest organ of the body. It can be easily examined but for many clinicians continues to be difficult to describe what they are seeing. Analo...
Source: PediatricEducation.org - April 25, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news
Kylie Jenner flaunts post-baby body in classy denim outfit on Easter: pic
Kylie Jenner is reclaiming her fashion icon tags after welcoming a baby buy as she flaunted her post-baby body in a classy denim outfit on Easter.Taking to Instagram, the 24-year-old reality TV... #realitytvstar #kyliejenner
Source: Reuters: Health - April 18, 2022 Category: Consumer Health News Source Type: news
A Russian woman is jailed for replacing store price tags with anti-war messages
Source: Reuters: Health - April 14, 2022 Category: Consumer Health News Source Type: news
Scientific evidence supporting the government response to coronavirus (COVID-19), SAGE (updated 8th April 2022)
Evidence considered by the Scientific Advisory Group for Emergencies (SAGE).
8 April 2022We ' ve added 38 papers under February to December 2020, and 6 new papers under January, March and June 2021. We ' ve also published 6 medium-term projections that were considered during a week in which no SAGE was held.
18 February 2022We ' ve added 10 new papers to February 2022 and added an HTML version of one paper. We ' ve also corrected the author attribution of a paper from April 2020.
Source: Current Awareness Service for Health (CASH) - April 8, 2022 Category: Consumer Health News Source Type: news
Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Role identifier badges can assist patients, reduce perceptions of bias in health care setting, Mayo Clinic study finds
ROCHESTER, Minn. — Patients see a wide variety of medical professionals during a hospital stay, and it can be challenging for them to remember the titles and roles of everyone involved in their care. Many hospitals use name tags and other visual cues to help patients know who's providing their care, but misidentif ication remains an issue. Resident physicians are often misidentified by patients and colleagues in hospitals, and it's especially common for female residents, according…
Source: News from Mayo Clinic - April 1, 2022 Category: Databases & Libraries Source Type: news
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Media News - March 30, 2022 Category: Pharmaceuticals Source Type: news
